Plant Name: Forsythia suspense
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.157E-11 | 2.291E-08 | CA1, CA12, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9, MMP1, MMP2, MMP9, NR1H4, PPARA, PPARD, PTPN1 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.195E-07 | 2.078E-04 | CYP1A2, CYP2C19, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 2.860E-07 | 2.395E-04 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.315E-06 | 6.826E-04 | AKR1B1, AKR1B10, CYP1A2, CYP2C19, CYP3A4, NR1H4, PPARD |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.392E-06 | 1.085E-03 | CYP1A2, CYP2C19, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 6.184E-06 | 2.494E-03 | NFKB1, NR1H4, PPARA, PPARD, PTPN2 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.519E-05 | 5.012E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 1.519E-05 | 5.012E-03 | GPBAR1, NR1H4 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.519E-05 | 5.012E-03 | ADRA2A, ADRA2C |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 1.519E-05 | 5.012E-03 | GPBAR1, NR1H4 |
| BP | GO:0051179; localization | GO:0046903; secretion | 1.639E-05 | 5.306E-03 | CA2, CA9, FABP5, GAA, MAPK1, MMP9, NFKB1, NMUR2, NR1H4, PLA2G1B, TLR2 |
| BP | GO:0065007; biological regulation | GO:0010817; regulation of hormone levels | 1.692E-05 | 5.340E-03 | ACHE, ADRA2A, ADRA2C, AKR1B1, CYP3A4, NFKB1, NR1H4, PPARD |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 2.273E-05 | 6.512E-03 | MMP1, MMP2, MMP9, PLA2G1B |
| BP | GO:0009987; cellular process | GO:0033554; cellular response to stress | 2.318E-05 | 6.554E-03 | AKR1B1, CA2, CA9, LMNA, MAP2K1, MAPK1, MAPT, MMP9, NFKB1, POLB, PPARD, PTPN1, TDP1 |
| BP | GO:0065007; biological regulation | GO:0032431; activation of phospholipase A2 activity | 3.034E-05 | 7.181E-03 | NMUR2, PLA2G1B |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 3.034E-05 | 7.181E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 3.034E-05 | 7.181E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0090170; regulation of Golgi inheritance | 3.034E-05 | 7.181E-03 | MAP2K1, MAPK1 |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 3.034E-05 | 7.181E-03 | PTPN1, PTPN2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.034E-05 | 7.181E-03 | CYP1A2, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:1901701; cellular response to oxygen-containing compound | 4.208E-05 | 9.553E-03 | AKR1B1, MAPK1, MMP2, MMP9, NFKB1, NR1H4, PLA2G1B, PPARD, TLR2 |
| BP | GO:0009987; cellular process | GO:0001775; cell activation | 4.731E-05 | 9.953E-03 | ADRA2A, ADRA2C, FABP5, GAA, MAPK1, MAPT, MMP9, NFKB1, PTPN2, TLR2 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 4.741E-05 | 9.953E-03 | CYP1A2, MAPK1, MMP9 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.718E-24 | 8.097E-20 | CA1, CA12, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.933E-18 | 3.193E-14 | CA1, CA12, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 6.202E-17 | 2.701E-13 | CA1, CA12, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.695E-23 | 2.492E-21 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA7; CA6; CA9; CA14 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.474E-10 | 1.083E-08 | FABP2; FABP3; FABP4; FABP5; MMP1; PPARA; PPARD |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.880E-08 | 1.411E-06 | MAP2K1; MMP1; MMP2; MAPK1; MMP9 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.648E-07 | 1.708E-05 | PLA2G1B; CYP1A2; CYP3A4; CYP2C19 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 7.391E-06 | 2.173E-04 | MAP2K1; MAPK1; NFKB1; PPARD |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.343E-05 | 4.919E-04 | MAP2K1; MMP1; MMP2; MAPK1; MMP9; NFKB1; PPARD |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.671E-05 | 4.094E-04 | MAP2K1; MAPK1; MMP9; NFKB1; TLR2 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 8.073E-05 | 1.149E-03 | MAP2K1; MMP2; MAPK1; MMP9; TLR2 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 6.587E-05 | 1.076E-03 | MAP2K1; MMP2; MAPK1; MMP9 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 8.595E-05 | 1.149E-03 | MAP2K1; MAPK1; NFKB1; TLR2 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 9.925E-05 | 1.216E-03 | MAP2K1; MAPK1; MMP9; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.344E-04 | 2.638E-03 | MAP2K1; MAPK1; MAPT; NFKB1; CDC25B |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.512E-04 | 2.638E-03 | MAP2K1; LMNA; MAPK1; NFKB1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 3.869E-05 | 7.110E-04 | AKR1B10; GAA; AKR1B1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 4.719E-04 | 3.547E-03 | MAP2K1; MAPK1; MMP9; NFKB1; CDC25B |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 4.127E-04 | 3.547E-03 | MAP2K1; MAPK1; NFKB1 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 4.907E-04 | 3.547E-03 | MAP2K1; MAPK1; ADRA2C; ADRA2A |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 4.703E-04 | 3.547E-03 | CYP1A2; CYP3A4; CYP2C19 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 5.329E-04 | 3.547E-03 | MAP2K1; MAPK1; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 5.549E-04 | 3.547E-03 | MAP2K1; MAPK1; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 5.549E-04 | 3.547E-03 | MAP2K1; MAPK1; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 9.456E-04 | 5.560E-03 | MAP2K1; MAPK1; PPARA; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 5.115E-04 | 3.547E-03 | CA2; NR1H4; CYP3A4 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 5.549E-04 | 3.547E-03 | MAPK1; NFKB1; TLR2 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 9.887E-04 | 5.590E-03 | MAP2K1; MAPK1; NFKB1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.424E-03 | 6.902E-03 | MMP2; MAPK1; NFKB1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.054E-03 | 5.741E-03 | MAP2K1; MMP2; MAPK1 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.537E-03 | 6.902E-03 | MAP2K1; PLA2G1B; MAPK1; NFKB1 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 1.306E-03 | 6.857E-03 | MAP2K1; MAPK1; CDC25B |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 7.793E-04 | 4.773E-03 | CYP1A2; CYP3A4; CYP2C19 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.507E-03 | 6.902E-03 | MAP2K1; MAPK1; NFKB1 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.867E-03 | 7.411E-03 | ACHE; MAP2K1; MAPK1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.549E-03 | 6.902E-03 | MAP2K1; MAPK1; NFKB1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.549E-03 | 6.902E-03 | MAPK1; NFKB1; TLR2 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.773E-03 | 7.411E-03 | PTPN1; PPARA; NFKB1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.916E-03 | 7.411E-03 | MAP2K1; MAPK1; CYP2C19 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 2.223E-03 | 7.972E-03 | MAPK1; NFKB1; TLR2 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 2.332E-03 | 7.972E-03 | MAP2K1; MAPK1; NFKB1 |
| hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 2.332E-03 | 7.972E-03 | MAP2K1; PLA2G1B; MAPK1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.332E-03 | 7.972E-03 | MAP2K1; MAPK1; NFKB1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 5.101E-03 | 1.500E-02 | AKR1B10; PLA2G1B; GAA; CYP1A2; AKR1B1; CYP2C19; CYP3A4; HSD17B10 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 3.054E-03 | 9.759E-03 | MAP2K1; MAPK1; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 3.120E-03 | 9.759E-03 | MAPK1; PPARA; NFKB1 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 3.533E-03 | 1.082E-02 | PTPN1; MAP2K1; MAPK1 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 6.589E-03 | 1.773E-02 | MAP2K1; MAPK1; NFKB1; TLR2 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 5.990E-03 | 1.693E-02 | MAPK1; MAPT; HSD17B10 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 6.704E-03 | 1.773E-02 | MAP2K1; MAPK1; NFKB1 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 7.024E-03 | 1.780E-02 | MAPK1; NFKB1; TLR2 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 8.041E-03 | 1.860E-02 | MAP2K1; MAPK1; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.032E-02 | 2.036E-02 | POLB; MAPK1; NFKB1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 5.849E-03 | 1.686E-02 | MAP2K1; MAPK1 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 2.292E-02 | 3.703E-02 | NMUR2; ADRA2C; ADRA2A |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 6.756E-03 | 1.773E-02 | MAP2K1; MAPK1 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 6.523E-03 | 1.773E-02 | NFKB1; TLR2 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 7.972E-03 | 1.860E-02 | MAP2K1; MAPK1 |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 7.722E-03 | 1.860E-02 | MAP2K1; MAPK1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.849E-03 | 7.411E-03 | MAP2K1; MAPK1 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 3.000E-02 | 4.691E-02 | MAP2K1; MAPK1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 6.992E-03 | 1.780E-02 | MAPK1; NFKB1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 2.779E-02 | 4.393E-02 | MAP2K1; MAPK1 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.572E-02 | 2.818E-02 | MAP2K1; MAPK1 |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 1.783E-02 | 3.083E-02 | MAP2K1; MAPK1 |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 2.043E-02 | 3.374E-02 | MAP2K1; MAPK1 |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 2.043E-02 | 3.374E-02 | NFKB1; TLR2 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 9.011E-03 | 1.920E-02 | MAP2K1; MAPK1 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 2.081E-02 | 3.400E-02 | MAP2K1; MAPK1 |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 2.779E-02 | 4.393E-02 | MMP2; MMP9 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 7.475E-03 | 1.831E-02 | AKR1B10; AKR1B1 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 9.828E-03 | 1.979E-02 | MAP2K1; MAPK1 |
| hsa00564 | Glycerophospholipid metabolism_Homo sapiens_hsa00564 | 1.856E-02 | 3.172E-02 | ACHE; PLA2G1B |
| hsa05323 | Rheumatoid arthritis_Homo sapiens_hsa05323 | 1.676E-02 | 2.933E-02 | MMP1; TLR2 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 8.226E-03 | 1.860E-02 | MAP2K1; MAPK1 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 1.603E-03 | 6.932E-03 | MAP2K1; MAPK1 |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 1.892E-02 | 3.198E-02 | CA2; PLA2G1B |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 9.011E-03 | 1.920E-02 | CYP1A2; CYP3A4 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 9.280E-03 | 1.921E-02 | MAP2K1; MAPK1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 9.552E-03 | 1.950E-02 | MAP2K1; MAPK1 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 1.606E-02 | 2.845E-02 | MAP2K1; MAPK1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.068E-02 | 2.065E-02 | MAP2K1; MAPK1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.538E-02 | 2.791E-02 | MAPK1; NFKB1 |
| hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 9.280E-03 | 1.921E-02 | MAP2K1; MAPK1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 7.231E-03 | 1.802E-02 | CYP1A2; CYP3A4 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 9.011E-03 | 1.920E-02 | NFKB1; TLR2 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 1.039E-02 | 2.036E-02 | PPARA; NFKB1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 8.226E-03 | 1.860E-02 | PLA2G1B; CYP2C19 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.156E-02 | 2.150E-02 | PTPN1; MAPK1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 9.011E-03 | 1.920E-02 | MAPK1; NFKB1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.126E-02 | 2.122E-02 | CYP1A2; CYP3A4 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.186E-02 | 2.179E-02 | MAPK1; NFKB1 |
| hsa05020 | Prion diseases_Homo sapiens_hsa05020 | 2.688E-03 | 8.979E-03 | MAP2K1; MAPK1 |
| hsa04975 | Fat digestion and absorption_Homo sapiens_hsa04975 | 3.673E-03 | 1.102E-02 | FABP2; PLA2G1B |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 2.250E-03 | 7.972E-03 | AKR1B10; AKR1B1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 2.842E-03 | 9.283E-03 | AKR1B10; AKR1B1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.095E-02 | 2.091E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2 |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2; MMP2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA2C; ADRA2A; ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; PPARD; NFKB1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; MAPK1; MMP9; TLR2; MMP2 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; PPARD; PPARD; ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; ADRA2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; AKR1B1; PLA2G1B |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA1; CA9; MAPK1; MMP9; NFKB1; TLR2; MMP2; ACHE; CDC25B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; AKR1B1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C; ACHE |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| NA: NA | Edema | NA | CA2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2 |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| NA: NA | Dyslipidemia | NA | PPARD |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C; PLA2G1B |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ADRA2C; ACHE; ACHE; ACHE; MAPT |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1; ADRA2C; ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; PLA2G1B |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADRA2C; PLA2G1B |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |